The holy grail of regenerative pharmacology.
ME-Regen® is our protein-engineering platform for in-situ tissue regeneration. By delivering microgram doses with 2–4 week retention, it activates the body's own repair cascade without the systemic exposure of conventional high-dose therapies.
Tissue regeneration needs the right molecule, at the right place, at the right time — for long enough.
Most regenerative therapies fail because they deliver a growth factor in a bolus — a spike that lasts hours, not weeks. The body's cells need sustained exposure to the right signal to commit to a regeneration program. ME-Regen® solves this with protein-engineering technology that controls the release profile at the site of action.
The result: lower doses, longer effect, lower systemic exposure, lower risk of off-target effects (including tumorigenicity).
Release profile — schematic
Illustrative. Actual release profile is protein-specific and tunable.
The four levers of ME-Regen®.
Microgram-level precision
Delivery at µg-level, vs. the mg-level of conventional bolus dosing. Reduces systemic exposure by 100–1,000x.
2–4 weeks effective retention
Active protein presence extended to weeks, vs. hours for bolus. Gives cells sustained exposure to commit to regeneration programs.
Release kinetics on demand
Formulation parameters are tuned per protein, per tissue, per clinical scenario. Linear, zero-order, or staged release.
Reduced off-target risk
Localised delivery minimises systemic exposure, reducing risks of off-target effects and tumorigenicity.
From bone to neural. A platform with broad reach.
ME-Regen® is protein-agnostic and indication-agnostic. Our current internal R&D pipeline targets four high-value areas.
Where ME-Regen® is today.
Core R&D is complete. Pilot-scale and pre-clinical studies are the next milestone.
Core R&D closed-loop
Formulation platform validated. Multiple proteins formulated and characterised in vitro.
Pilot scale-up
Pilot manufacturing in progress at our 800 m² facility. Expansion at Phase II 5,000 m² site.
Pre-clinical & clinical
Pre-clinical toxicology & efficacy studies planned. First IND/CTA filing targeted for 2027.
Partner with us on ME-Regen®.
Pharmaceutical, biotech, and medtech partners — let's explore co-development, in-licensing, or co-marketing opportunities.